Skip to main content
MD
NYSE Industrial Applications And Services

Pediatrix Q3 Adjusted EPS $0.72; Full-Year EBITDA Guidance Raised to $290M-$300M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$28.6
Mkt Cap
$2.349B
52W Low
$16.9
52W High
$30.045
52W Position info
69% above low
Off High info
4.8% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

MD sits 69% above its 52-week low of $16.9.

Summary

Pediatrix reported Q3 Adjusted EPS of $0.72 on $501.4M revenue and raised the low end of its 2026 Adjusted EBITDA guidance to $290M-$300M, while spending $83.0M on buybacks in the quarter.


Key Events · Earnings and Guidance · MD

  • Q3 Adjusted EPS Beats at $0.72

    Net income of $47.0M, or $0.59 per diluted share, on net revenue of $501.4M; Adjusted EPS of $0.72 versus $0.67 a year earlier.

  • Full-Year EBITDA Guidance Raised

    The 2026 Adjusted EBITDA outlook is now $290M-$300M, up from the $280M-$300M range reaffirmed with Q2 results on 2026-08-04; nine-month Adjusted EBITDA was $220.1M.

  • $83M Buyback Shrinks Share Count

    Q3 share repurchases of $83.0M cut weighted average diluted shares to 79.7M from 85.6M a year ago, adding to per-share results.

  • Balance Sheet: $312M Cash, $578M Debt

    Cash and equivalents of $311.9M at September 30, 2026 against total debt of $578M ($400M 5.375% Senior Notes due 2030 plus $178M Term A Loan); no revolver borrowings outstanding.


Analysis · MD · Industrial Applications And Services

The headline for Pediatrix is the raised floor on full-year Adjusted EBITDA guidance: the outlook now sits at $290M-$300M, up from the $280M-$300M range reaffirmed in August. Top-line results also came in ahead, with Q3 revenue of $501.4M up 1.7%. Adjusted EBITDA of $85.5M was slightly below last year's $87.3M, so the raise leans on the first nine months ($220.1M) plus a stronger fourth quarter. Buybacks are doing real work in per-share results: $83.0M spent on repurchases in the quarter cut diluted shares to 79.7M from 85.6M a year ago, helping lift Adjusted EPS to $0.72 from $0.67. With the stock near its 52-week high, the guidance raise is the number that matters.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MD was trading at $28.60 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $16.90 to $30.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MD - Latest Insights

MD
Oct 29, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $28.60
Real-time Price: $31.30 info
Change: +$2.70 (+9%) info
Market Cap: $2.445B info
MD
Oct 29, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $28.60
Real-time Price: $31.30 info
Change: +$2.70 (+9%) info
Market Cap: $2.445B info
MD
Aug 04, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $25.05
Real-time Price: $31.30 info
Change: +$6.25 (+25%) info
Market Cap: $2.445B info
MD
Aug 04, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.68
Real-time Price: $31.30 info
Change: +$5.62 (+22%) info
Market Cap: $2.445B info
MD
Aug 04, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $25.68
Real-time Price: $31.30 info
Change: +$5.62 (+22%) info
Market Cap: $2.445B info